Phase I Clinical Trial of Islet Antigen–Specific Plasmid Coexpressing Tolerogenic Proteins Demonstrates Safety in Adults With Type 1 Diabetes
Authors:
- Carla J. GreenbaumCGCarla J. Greenbaum
- S. Alice LongSLS. Alice Long
- Stephen E. GitelmanSGStephen E. Gitelman
- Jason L. GagliaJGJason L. Gaglia
- Todd M. BruskoTBTodd M. Brusko
- Jeffrey P. KrischerJKJeffrey P. Krischer
- Michael J. HallerMHMichael J. Haller
- Andrea K. SteckASAndrea K. Steck
- Linda A. DiMeglioLDLinda A. DiMeglio
- 21 January 2026
- journal article
- Published by American Diabetes Association in Diabetes
- Vol. 75 (3) , 506-518
Abstract
There is significant interest in antigen-specific approaches to delaying type 1 diabetes in preclinical stages and supporting tolerance after diagnosis. We conducted a phase I trial of a nonintegrating DNA plasmid constructed to secrete the type 1 diabetes antigen preproinsulin (PPI) and the immune modulatory cytokines transforming growth factor-β1 (TGF-β1), interleukin-10 (IL-10), and IL-2. In this placebo-controlled, double-masked study of 47 adults with stage 3 type 1 diabetes, we showed that the drug is safe and well tolerated, with most reported adverse events (AEs) categorized as grade 1 and with no clinically significant difference in AEs among treatment groups. There were no untoward metabolic or immune effects. We found pharmacodynamic evidence of treatment, as demonstrated by a dose-dependent type 1 interferon (IFN) signature. Plasmid DNA, representing a pharmocokinetic measure, was detected in the two highest dosing groups. We did not find global or antigen-specific immune cell changes following treatment with a DNA plasmid expressing PPI, IL-2, IL-10, and TGF-β1, and we did not detect immune changes driven by IL-2, IL-10, or TGF-β1. Our results support further trials of this novel tolerizing antigen construct. Article Highlights: Antigen-specific therapy is needed to induce tolerance in type 1 diabetes at early disease stages or in combination with immunotherapy. We conducted a phase I trial in type 1 diabetes of a novel plasmid construct expressing the islet antigen preproinsulin (PPI) and immunomodulatory cytokines transforming growth factor-β1 (TGF-β1), interleukin-10 (IL-10), and IL-2. The therapy was safe and well tolerated. Dose-dependent changes in DNA plasmid levels and type 1 interferon signatures were detected; however, global and antigen-specific immune changes to PPI, IL-2, IL-10, or TGF-β1 were not observed. Further trials are needed to assess efficacy.Keywords
All Related Versions
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK061010)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK061034)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK061040)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK061042)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK061058)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK085453)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK085461)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK085465)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK085466)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK085476)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK085504)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK085509)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK103153)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK103282)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK106984)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK106993)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK106994)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK107014)
This publication has 37 references indexed in Scilit:
- IL-2 therapy in type 1 diabetes: “Trials” and tribulationsClinical Immunology, 2013
- Plasmid-Encoded Proinsulin Preserves C-Peptide While Specifically Reducing Proinsulin-Specific CD8 + T Cells in Type 1 DiabetesScience Translational Medicine, 2013
- Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell FunctionDiabetes, 2012
- Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in miceJournal of Clinical Investigation, 2012
- Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trialThe Lancet, 2011
- Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trialThe Lancet, 2011
- Robust relationship inference in genome-wide association studiesBioinformatics, 2010
- Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell FunctionNew England Journal of Medicine, 2009
- Mixed-Meal Tolerance Test Versus Glucagon Stimulation Test for the Assessment of β-Cell Function in Therapeutic Trials in Type 1 DiabetesDiabetes Care, 2008
- Effects of Oral Insulin in Relatives of Patients With Type 1 DiabetesDiabetes Care, 2005